Search Medical Condition
Please enter condition
Please choose location

Harlingen, Texas Clinical Trials

A listing of Harlingen, Texas clinical trials actively recruiting patient volunteers.

RESULTS

Found (11) clinical trials

Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

Improving reperfusion status is the most effective therapeutic approach for patients with acute ischemic strokes (AIS) due to large artery occlusion (LAO). Intra-Arterial Therapy (IAT) by means of mechanical thrombectomy and/or chemical fibrinolysis has been adopted worldwide to recanalize LAO strokes. IAT is now the standard of care for AIS ...

Phase N/A

0.54 miles

Learn More »

informCLL : A Disease Registry for Patients With Chronic Lymphocytic Leukemia

InformCLL is a multicenter, prospective, observational registry of CLL patients designed to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens. The registry will provide information on regimens used to treat first-line and later lines of CLL/SLL as ...

Phase N/A

0.54 miles

Learn More »

Post Market Surveillance Study of the Wingspan Stent System

This research study is a Food and Drug Administration (FDA) mandated post market surveillance study of the Wingspan® Stent System, also known as the WEAVE™ Trial. The purpose of this trial is to fulfill a FDA requirement to evaluate the rate of stroke and/or death within 72 hours of the ...

Phase N/A

0.54 miles

Learn More »

Utility of PharmacoGenomics for Reducing Adverse Drug Effects

UPGRADE aims to see whether data from Pharmacogenomic Testing (PGx) can help physicians manage patient medication regimens and assess if the testing has an effect on reducing adverse drug reactions, hospitalizations and emergency department visits. The way an individual processes a drug is in part determined by their genes, and ...

Phase N/A

0.54 miles

Learn More »

The Circulating Cell-free Genome Atlas Study

This is a prospective, multi-center, observational study with collection of de-identified biospecimens and clinical data from at least 15,000 participants from clinical networks in the United States and Canada. The study will enroll approximately 10,500 cancer subjects with multiple types of malignancies (CANCER arm) and approximately 4,500 representative subjects without ...

Phase N/A

0.54 miles

Learn More »

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Oversight Authorities continued: Colombia- pending regulatory approval

Phase

0.54 miles

Learn More »

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, is a prospective, randomized, double-blind, multicenter trial with the primary null hypothesis that, in patients with TIA or minor ischemic stroke treated with aspirin 50-325 mg/day, there is no difference in the event-free survival at 90 days in those ...

Phase

0.54 miles

Learn More »

Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium

Due to the lack of information generated in the pivotal phase III trials assessing potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium, the FDA requested clinical information from a 1-year (minimum) clinical study to support that there are no adverse effects on the corneal ...

Phase

0.54 miles

Learn More »

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

Title Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized, open-label, controlled, phase 3 clinical trial Hypotheses Seventeen (17) week rifapentine-based regimen In previously untreated individuals with active drug-susceptible pulmonary tuberculosis treated with eight weeks of rifapentine (P), isoniazid (H), pyrazinamide (Z) and ethambutol (E) followed by nine weeks of ...

Phase

0.54 miles

Learn More »

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial is a multicenter, randomized, controlled clinical trial of 1400 patients that will include approximately 60 enrolling sites. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose concentration (80mg/dL - 130 mg/dL) will be safe and result ...

Phase

3.19 miles

Learn More »